Gilead Sciences (GILD) DIvidends Date & History

Key Takeaways

• GILD offers a current dividend yield of approximately 2.17% with an annual payout of $3.28 per share.
• The company pays dividends quarterly and has increased its dividend for 11 consecutive years since initiating payments in 2015.
• Free cash flow provides strong coverage for the dividend, supporting long-term sustainability despite variable earnings.
• Dividend growth has been modest but consistent, averaging around 3% annually in recent years.
• The payout appeals primarily to income-focused investors seeking stability in the healthcare sector.
• Relative to peers, the yield sits in line with many large-cap pharmaceutical and biotechnology companies.

Dividend Overview

GILD pays a quarterly dividend currently set at $0.82 per share, for an annualized total of $3.28. This translates to a trailing yield near 2.17% based on recent share prices. Gilead Sciences initiated its dividend program in 2015 and follows a policy of regular quarterly distributions with periodic increases. The stock is positioned as a modest-yield dividend payer rather than a high-yield income vehicle, with emphasis on consistency and gradual growth supported by robust cash generation from its core HIV franchise.

Dividend History and Growth

Gilead Sciences has maintained uninterrupted quarterly dividend payments since 2015, marking 11 years of consistent distributions. The quarterly amount has risen steadily from $0.43 in 2015 to the current $0.82 level. Annualized growth rates have averaged approximately 3% over the past five years, reflecting a conservative approach to increases that prioritizes sustainability. No dividend cuts have occurred, and the company has demonstrated a commitment to returning capital through both dividends and share repurchases.

Dividend Sustainability and Payout Ratio

The dividend appears well-supported by free cash flow. In recent periods, free cash flow payout ratios have remained below 35%, providing a comfortable cushion. While reported earnings payout ratios have fluctuated due to one-time items and R&D spending, operating cash flow of over $10 billion in fiscal 2025 comfortably covered the roughly $4 billion in annual dividends. Strong balance sheet metrics and patent protection on key products through 2036 further bolster sustainability.

Dividend Compared to Industry Peers

Within the healthcare sector, GILD’s yield of approximately 2.17% compares closely with peers such as Amgen, AbbVie, and Bristol-Myers Squibb, which typically offer yields between 1.5% and 3.5%. Gilead’s profile aligns more with established biotechnology and pharmaceutical names that prioritize moderate yields paired with growth potential rather than the higher yields seen in some mature healthcare companies.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.

Is This Stock Attractive for Dividend Investors?

GILD may suit income-oriented investors who value steady quarterly payments and a track record of modest annual increases over high current yields. Dividend growth investors could find appeal in the consistent history and strong free cash flow coverage that supports future raises. Conservative long-term holders in the healthcare space may appreciate the balance between income and the company’s established product portfolio. The stock is less ideal for those seeking high yields or rapid dividend expansion. Investors should consider the company’s revenue concentration in HIV therapies and ongoing pipeline developments when evaluating suitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations